Hims & Hers (HIMS) Investors Pulling Their Hair Out Over Pills Side-Effects
Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...
They Wanted a Quick Fix for Hair Loss. Instead, These Young Men Got Sick.
Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.
Zacks Investment Research on MSN1d
Hims & Hers Stock Gains 8.6% in Three Months: How to Play It?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Hims & Hers to shut down dermatology business Apostrophe
Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?
Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...
Hims & Hers bought a skincare startup for $190 million 4 years ago. Today it shut it down.
Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...
Bay Area startup, a few years after being bought for $131M, shuts down
Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Hims & Hers: A Generational Dip-Buying Opportunity
Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...
Tidal Trust II - Defiance Daily Target 2X Long HIMS ETF
U.S. News compares companies to their industry peers based on a variety of company fundamentals, performance metrics and investor preferences to help you find the right stocks for your investing style ...